{"meshTags":["Angiogenesis Inhibitors","Carcinoma, Non-Small-Cell Lung","DNA Mutational Analysis","Female","Genes, erbB-1","Genetic Predisposition to Disease","Humans","Lung Neoplasms","Male","Mutation","Prognosis","Protein-Tyrosine Kinases","Receptor, Epidermal Growth Factor","Risk Assessment","Survival Analysis","Treatment Outcome"],"meshMinor":["Angiogenesis Inhibitors","Carcinoma, Non-Small-Cell Lung","DNA Mutational Analysis","Female","Genes, erbB-1","Genetic Predisposition to Disease","Humans","Lung Neoplasms","Male","Mutation","Prognosis","Protein-Tyrosine Kinases","Receptor, Epidermal Growth Factor","Risk Assessment","Survival Analysis","Treatment Outcome"],"genes":["epidermal growth factor receptor tyrosine kinase","EGFR","Small molecule tyrosine kinase","epidermal growth factor receptor","EGFR","EGFR gene","EGFR tyrosine kinase","EGFR"],"publicationTypes":["Journal Article","Review"],"abstract":"Small molecule tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR) are important agents in the treatment of non-small cell lung cancer (NSCLC) and have enhanced activity in the subpopulation of patients with NSCLC who harbor somatic activating mutations of the EGFR gene. This review summarizes the data describing the use of EGFR tyrosine kinase inhibitors in a genotype-directed population of NSCLC patients with EGFR mutations and discusses areas that require further study.","title":"First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation: positive non-small cell lung cancer patients.","pubmedId":"18520299"}